Mode
Text Size
Log in / Sign up

Non-Randomized Pilot Trial Evaluates Aurora Digital CBT Plus Medication for Generalized Anxiety DisorderDigital Therapy Adds Relief for Anxiety Patients in Mexico

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret findings with caution as a non-randomized pilot suggests potential adjunctive benefits for anxiety.

This multicenter pilot, non-randomized clinical trial enrolled 34 adults with generalized anxiety disorder receiving stable pharmacological treatment. The study compared Aurora, a Spanish-language, culturally adapted digital cognitive behavioral therapy program plus medication, against medication alone. Assessments occurred at baseline and weeks 4, 8, and 12, with follow-up completed at 12 weeks.

Anxiety severity (GAD-7) showed a significant effect of time with reductions across both groups (F3,96 = 169.65, p < 0.001). Pathological worry (PSWQ) demonstrated greater reductions in the Aurora group, particularly at weeks 8 and 12 (group F1,31.12 = 6.96, p = 0.013; interaction F3,93.4 = 7.86, p < 0.001). At week 12, the intervention group had higher odds of lower worry severity (OR = 12.5, p = 0.004). Depressive symptoms decreased similarly in both groups, though specific statistical values were not reported.

Safety profiles were favorable with comparable adverse-event incidence and no serious adverse events reported. Discontinuations were not reported. Key limitations include the non-randomized design, small sample size, and baseline imbalances. Practice relevance is preliminary, hypothesis-generating evidence that a culturally adapted digital CBT intervention can be safely integrated with pharmacotherapy and may be associated with enhanced improvements in anxiety-related outcomes. Causal inference is limited by the non-randomized study design.

Constant worry can feel like a heavy weight on your chest. It keeps you up at night and makes simple tasks feel impossible. Millions of people live with this feeling every single day.

Anxiety disorders are among the top causes of disability worldwide. Many people struggle to find help that fits their lives.

Worrying Too Much Is Not Normal

Standard medication helps calm the body, but it does not always quiet the mind. Some patients still feel stuck in a loop of negative thoughts.

This is where therapy usually steps in. Traditional talk therapy requires time, travel, and often high costs.

Access to these services remains limited in many middle-income countries. People often wait months for an appointment that might not cover their specific needs.

A Digital Tool for Mental Health

Researchers tested a new solution called Aurora. This is a digital program designed specifically for Spanish speakers.

It brings cognitive behavioral therapy directly to a phone or tablet. The content respects cultural nuances that standard apps often miss.

Think of it like a personal trainer for your thoughts. It guides users through exercises that retrain how they react to stress.

The program runs alongside regular medication. It does not replace the drugs but adds a layer of support.

The App Worked Better Than Meds Alone

A pilot study followed thirty-four adults over three months. Half used the app with their medication, while the other half took only the medicine.

Everyone started with stable doses of their prescribed drugs. The researchers checked in at four, eight, and twelve weeks.

This does not mean the app is ready for everyone.

The group using the app reported significantly less worry. They felt better at the eight and twelve-week marks compared to the control group.

Anxiety scores dropped for everyone, but the drop was deeper for app users. Worry specifically decreased more than general anxiety symptoms.

Depression symptoms improved similarly in both groups. This suggests the app targets worry specifically rather than lifting all mood issues at once.

Why This Study Needs More Time

The results look promising, but the study had limits. It was small and did not randomly assign participants to groups.

This means we cannot say for sure the app caused the improvement. Other factors might have influenced the outcome.

The participants were mostly women with an average age of forty. Results might differ for men or older adults.

Safety monitoring showed no serious side effects. The digital program appeared safe to use alongside standard care.

If you live in Mexico or speak Spanish, this offers hope. It shows that technology can fill gaps in mental health care.

You should talk to your doctor before trying new tools. They can help you decide if this fits your current treatment plan.

Do not stop taking your medication without medical advice. The app is meant to add support, not replace your prescription.

Larger trials are now needed to confirm these findings. Scientists want to see if the benefits last for years.

They also need to test this in different countries. The cultural adaptation might need tweaking for other regions.

Funding and approval processes will take time. But this pilot proves the concept works in a real-world setting.

Mental health care is evolving to meet people where they are. Digital tools like Aurora could become a standard part of that future.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
Background/objectiveAnxiety and depressive disorders are leading causes of disability worldwide, and access to evidence-based psychological treatment remains limited in many middle-income countries. Digital cognitive–behavioral therapy (CBT) interventions have emerged as scalable tools to address this treatment gap, yet few have undergone clinical evaluation in Latin American populations. This study aimed to assess the safety and preliminary efficacy of Aurora, a Spanish-language, culturally adapted digital CBT program, when used as an adjunct to pharmacotherapy in adults with generalized anxiety disorder.MethodsIn a multicenter, open-label, non-randomized pilot study, 34 adults diagnosed with generalized anxiety disorder receiving stable pharmacological treatment were assigned through pragmatic, convenience-based allocation either to an experimental group (Aurora plus medication; n = 24) or to a control group receiving medication alone (n = 10). The sample had a mean age of 39.85 ± 12.88 years, with a predominance of women (22/34). Participants were followed for 12 weeks with assessments at baseline and weeks 4, 8, and 12. Clinical outcomes included anxiety severity measured by the Generalized Anxiety Disorder-7 (GAD-7), pathological worry assessed by the Penn State Worry Questionnaire (PSWQ), and depressive symptoms evaluated using the Patient Health Questionnaire-9 (PHQ-9). Safety was monitored through structured adverse-event reporting. Statistical analyses included linear mixed-effects models for longitudinal outcomes, ordinal logistic regression for severity transitions, and negative binomial regression and Fisher’s exact test for adverse events, with false discovery rate correction applied where appropriate.ResultsAurora demonstrated a favorable safety profile, with no serious adverse events and comparable adverse-event incidence between groups under structured clinical monitoring at weeks 4, 8, and 12. Anxiety symptoms (GAD-7) showed a significant effect of time (F3,96 = 169.65; p < 0.001), indicating reductions across both groups. Pathological worry (PSWQ) demonstrated significant group (F1,31.12 = 6.96; p = 0.013) and group × time interaction effects (F3,93.4 = 7.86; p < 0.001), with greater reductions in the Aurora group, particularly at weeks 8 and 12. At week 12, ordinal analyses indicated higher odds of lower worry severity in the intervention group (β = 2.53; p = 0.004; OR = 12.5). Depressive symptoms decreased similarly in both groups. Positive effect increased progressively across intervention modules, and module-embedded cognitive measures of anxiety and depression showed significant reductions over time.ConclusionThis pilot study provides preliminary, hypothesis-generating evidence that a culturally adapted digital CBT intervention can be safely integrated with pharmacotherapy and may be associated with enhanced improvements in anxiety-related outcomes, particularly pathological worry, in a Mexican clinical population. However, the non-randomized design, small sample size, and baseline imbalances limit causal inference and generalizability, and findings should be interpreted with caution. Larger randomized controlled trials are needed to confirm efficacy, determine long-term clinical impact, and guide the implementation of digital therapeutics in Latin American mental health systems.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.